𝐏𝐥𝐮𝐬 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐍𝐞𝐰 𝐈𝐧𝐭𝐞𝐫𝐢𝐦 𝐑𝐞𝐒𝐏𝐄𝐂𝐓-𝐆𝐁𝐌 𝐏𝐡𝐚𝐬𝐞 𝟐 𝐓𝐫𝐢𝐚𝐥 𝐃𝐚𝐭𝐚 𝐚𝐭 𝐭𝐡𝐞 𝐒𝐨𝐜𝐢𝐞𝐭𝐲 𝐟𝐨𝐫 𝐍𝐞𝐮𝐫𝐨𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐀𝐧𝐧𝐮𝐚𝐥 𝐌𝐞𝐞𝐭𝐢𝐧𝐠 𝐚𝐧𝐝 𝐰𝐢𝐥𝐥 𝐇𝐨𝐬𝐭 𝐊𝐞𝐲 𝐎𝐩𝐢𝐧𝐢𝐨𝐧 𝐋𝐞𝐚𝐝𝐞𝐫 𝐖𝐞𝐛𝐢𝐧𝐚𝐫 Plus Therapeutics, Inc. (Nasdaq: PSTV) Plus Therapeutics, Inc. shares encouraging results from the ongoing ReSPECT-GBM Phase 2 trial for rhenium (186Re) obisbemeda, its lead radiotherapeutic designed for recurrent glioblastoma (rGBM). Presented at the Society for NeuroOncology (SNO) 28th Annual Meeting, the data hints at a survival benefit over standard care, underlining potential advancements in glioblastoma treatment. Key Highlights: ReSPECT-GBM Phase 2 trial focuses on assessing overall survival (OS) post-administration of rhenium (186Re) obisbemeda. Preliminary data includes 15 treated rGBM patients, revealing a median overall survival of 13 months, with 9 patients still alive. Median progression-free survival stands at 11 months. Robust tumor coverage is reported, with 87.2% treated tumor volume in 15 patients at 120 hours. Longitudinal imaging analysis supports observed efficacy signals. Safety and tolerability align with Phase 1 trial data, marking rhenium (186Re) obisbemeda as generally safe and well-tolerated. Commentary: Marc H. Hedrick, M.D., M.B.A. Marc Hedrick, President and CEO of Plus Therapeutics, expressed optimism, stating, “We believe the data presented at SNO suggests that rhenium (186Re) obisbemeda confers a survival benefit over published standard of care data and our own real-world data assessments of propensity matched controls.” Principal investigator Dr. Andrew J. Brenner noted the compelling therapeutic rationale and observed Phase 2 clinical outcomes consistent with the Phase 1 trial. The 2024 focus for Plus Therapeutics involves expanding clinical sites, completing Phase 2 enrollment, advancing Phase 1 trials, and planning the next steps for the program. #clinicaltrials #oncology #treatment #therapeutics #tumor #healthcare
